Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVE-003 in Patients with Huntington's Disease (SELECT-HD)
NCT05032196Phase 2Completed
- Sponsor
- Wave Life Sciences
- Start
- Sep 2021
- Primary completion
- May 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 10
01
Overview
A Phase 2 trial of WVE-003 in Huntington disease (HD), sponsored by Wave Life Sciences. Started Sep 2021; status: completed.
02
Drugs
WVE-003
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT05032196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032196.